Medication for eczema that could have had a $20,000 increase in price is now available, bringing relief to those who suffer from the condition.

Throughout most of his life, Greg Giles has been plagued by the painful and debilitating skin condition known as eczema. In an interview with 9News, Giles shared his experience, saying, "I couldn't stop scratching, whether I was awake or asleep. It was like torture." This condition causes intense itching, redness, bleeding, and can even lead to infections. However, Giles has found relief through a new injectable treatment called Dupixent.

Speaking about his experience with Dupixent, Giles stated, "It was truly miraculous. Within a few weeks, my symptoms improved significantly." He is not alone in his positive experience with the medication, as nearly 20,000 Australians have also found relief since it was added to the Pharmaceutical Benefit Scheme in 2021. This treatment has proven to be more popular than expected, costing the federal government $270 million initially.

According to dermatologist Dr. Warren Weightman, Dupixent works quickly and has fewer side effects than older treatments. However, this year, there was a possibility that the medication would be removed from the PBS by the supplier, leaving patients to pay $20,000 for a prescription or go without treatment altogether. This news caused great concern for patients like Giles, who rely on the medication to manage their symptoms.

Fortunately, a new deal has been made to keep Dupixent on the scheme. In a statement, Health Minister Mark Butler announced, "As of December 1st, we have confirmation that patients can have confidence in the fact that this treatment will remain on the PBS." This is a huge relief for patients who would have otherwise faced a significant financial burden to continue their treatment.

Aside from providing much-needed relief for patients, Dupixent also reduces the need for follow-up appointments, saving patients from additional out-of-pocket costs. Dr. Weightman explained, "There were more patients in need of this treatment than initially anticipated. Now, with the increased funding, we can provide this treatment to all those who need it." This news brings hope to those suffering from eczema and reinforces the importance of accessible and affordable healthcare for all.

[This article has been trending online recently and has been generated with AI. Your feed is customized.]
[Generative AI is experimental.]